Rare disease biotech SpringWorks Therapeutics files for a $115 million IPO - (NASDAQ via NewsPoints Desk)

  • In a filing with the US Securities and Exchange Commission, SpringWorks Therapeutics disclosed plans to raise up to $115 million in an initial public offering, reported NASDAQ.

  • The company is developing the small molecule gamma secretase inhibitor nirogacestat, initially for the treatment of desmoid tumors, for which there are currently no FDA-approved therapies. 

  • Nirogacestat was granted both orphan drug and fast-track designations by the FDA in 2017, and a Phase III trial was initiated this past May.

To read more NewsPoints articles, click here.